About The Study: Compared with maternal vaccination with the respiratory syncytial virus (RSV) prefusion F protein (RSVpreF) vaccine, passive infant immunization with nirsevimab was associated with lower risks of RSV-related hospitalization and severe outcomes. These findings reflect the first RSV season with use of these immunization strategies in mainland France; their use should be reevaluated in future studies.
Corresponding Author: To contact the corresponding author, Marie-Joelle Jabagi, PharmD, PhD, email marie-joelle.jabagi@ansm.sante.fr .
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2025.24082)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2025.24082?guestAccessKey=9c1cceec-6663-4e89-89f2-5ef55557283a&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=122225
JAMA